Global Irritable Bowel Syndrome (IBS) Therapeutics Industry

Sep 08, 2011, 06:50 ET from Reportlinker

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Irritable Bowel Syndrome (IBS) Therapeutics Industry

http://www.reportlinker.com/p0611068/Global-Irritable-Bowel-Syndrome-IBS-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 50 companies including many key and niche players such as Abbott Laboratories, Alimentary Health Limited, Edusa Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Lexicon Pharmaceuticals, Pharmos Corporation, Salix Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., and Tioga Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 5

Irritable Bowel Syndrome: A Primer 5

Market Analysis 5

World IBS Market to Witness Substantial Growth Despite of

Anticipated Slump in the GI Therapeutics Market 5

New Drug Launches to Drive the Growth of Highly Underserved

IBS Market in Developed Markets 6

Select Drugs in Late Stage Clinical Development 6

Linaclotide: One of the Most Promising Pipeline Drugs with

Substantial Market Potential 7

Irritable Bowel Syndrome Represents a Major Therapeutic

Challenge 7

Available IBS Drugs: Treating the Symptoms, Not the Cause 7

A Comparison of Current and Previous Treatment for IBS 7

Select Drugs/Therapeutics Available for IBS Treatment by

Symptom 8

Involvement of the Brain-Gut Axis Emphasized the Role of

Serotonin in IBS 8

Serotonin 5-HT Receptors Led the Drug Development Pipeline 8

Lack of Selectivity Hampers Predominance of 5-HT Receptor

Class of Drugs 8

List of 5-HT Class Drug Withdrawals/Trial Failures 9

Amitiza Led the IBS-C Market in 2008-2009, New Drug Launches

Likely to Affect Sales 9

Safety Concerns of Available Drugs and Low Rate of Diagnosis

Limit Market Growth 9

Growth Drivers 10

IBS Market is Presently Highly Fragmented, Generecized, and

Under Served 10

Drug Development Programs Drive Market Growth in Developed

Countries 10

Product Co-development, Commercialization, and Licensing

Agreements 11

Other Growth Drivers 11

High Prevalence 11

Variable Diagnostic Criteria and IBS Prevalence 12

Growing Awareness 12

Multiple Treatment Approaches Make Way for Complementary

Medicines 12

Need for Diagnostic Markers 13

Development of Novel Therapies 13

3. DISEASE OVERVIEW 14

Prevalence 14

Table 1: Prevalence of IBS in Select Countries/Regions of the

World (includes corresponding Graph/Chart) 14

Prevalence by Gender: Higher Prevalence in Women 15

Symptoms of IBS 15

Comorbidities Associated with IBS 15

Classification of IBS Based on Symptoms 16

Diarrhea-predominant IBS or IBS-D 16

Constipation-predominant IBS or IBS-C 16

Alternating or Mixed Type IBS 16

List of Select Conditions that could be Misdiagnosed as IBS 16

Select Tests Recommended to Rule out GI Disorders Other than IBS 17

What Causes Irritable Bowel Syndrome 17

The Function of the Colon 17

IBS and the Enteric Nervous System 17

The Brain-Gut Interaction 17

Direct Control 18

Indirect Control 18

Etiology of Irritable Bowel Syndrome 18

Chronic Anxiety Mediated Visceral Hyperalgesia 18

Serotonin 19

5HT3 and 5HT4 Receptors 19

Genetic Factors 19

Gastrointestinal Infections 20

The Intestinal Bacteria 20

Diagnosis of Irritable Bowel Syndrome 20

IBS Diagnostic Protocols 20

The Rome III Criteria for IBS Diagnosis 21

IBS Diagnosis in Children 22

The Manning Criteria for IBS Diagnosis 22

4. TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) 23

Current Treatment Scenario 23

Combination Therapies Offer Limited Efficacy and Short-Term

Relief 23

An Overview of Select Treatment and Therapies for Irritable

Bowel Syndrome 24

Select Drug Classes Available for IBS Treatment 24

Dietary Fiber 24

List of Select Commercially Packaged Fibers 24

Bulk-forming Laxatives 25

Osmotic laxatives 25

List of Select Osmotic Laxatives 25

Poorly Absorbed Ions 25

Poorly Absorbed Sugars 25

Stimulant laxatives 26

List of Select Stimulant Laxatives by Type 26

Derivatives of Diphenylmethane 26

Derivatives of Anthraquinones 26

Emollients 26

Anti-Diarrheals 26

Antidepressants 27

Scientific Data Supports the Use of Antidepressants in IBS 27

Tricyclics: Preferred Class of Antidepressants for Treating IBS 27

Side Effects of TCAs 28

Antispasmodic Agents 28

Anticholinergic Agents 28

List of Select Anticholionergics 29

Peppermint Oil and Direct Smooth Muscle Relaxants 29

List of Select Direct Smooth Muscle Relaxants 30

Alternative Therapies 30

Probiotics 30

What are probiotics? 30

Role of Probiotics 30

Potential Use of Probiotics in IBS Management 30

Data from Research and Clinical Studies 31

Herbal Remedies 31

Psychotherapy 31

Others 31

5. PRODUCT APPROVALS IN THE PAST 32

Lotronex 32

Zelnorm 32

Amitiza 32

BENTYL® (dicyclomine hydrochloride) 33

Colpermin 33

Irribow (Ramosetron Hydrochloride) 34

6. PIPELINE ANALYSIS 35

Linaclotide 35

LX1031 35

XIFAXAN® (Rifaximin) 35

ASIMADOLINE 36

Drugs' Early Stage Clinical Trials 36

Select IBS Drugs in Early Stages of Clinical Trials 36

Review of Pipeline Drugs in the Past (2006) 37

7. CLINICAL TRIALS 38

Synergy Pharmaceuticals to Conduct Phase II/III Trial of

Plecanatide 38

Almirall and Ironwood Achieve Success in Second Phase III

Trial of Linaclotide in IBS-C 38

Oxy-Powder Demonstrates Success in IBS Test 39

Ironwood and Forest Achieve Positive Results in Phase 3 Trial

of Linaclotide 39

VSL 3 Proves Effective for Children Suffering from IBS 39

Salix's Xifaxan (Rifaximin) Found Effective on Non-C IBS Symptom 40

Lexicon Concludes Phase II Clinical Trial of LX1031 40

Ocera Achieves Positive Result in Phase 2 Proof-of-Concept

Trial of AST-120 40

Pharmos Achieves Positive Results in Phase 2b IBS Trial 41

Order-Made Souyaku to Commence IBS Drug Trials in the UK 42

8. RECENT INDUSTRY ACTIVITY 43

Tioga Receives Fast Track Status for Asimadoline in IBS-D 43

Canadian Institut Rosell Extends Partnership with Probi 43

Achieve Clinical Research Commences Clinical Trials for IBS 43

Wild Partners with Sterling Technology 44

AMRI Proposes New Drug For Irritable Bowel Syndrome 44

Salix Obtains FDA's Filing and Priority Review Approval for

XIFAXAN550 in Non-C IBS 44

Soligenix Receives US Patent for Beclomethasone Dipropionate

for IBS Treatment 45

Meda Takes Over Norgine's Over-the-Counter Drugs 45

Tioga Reaches Agreement with FDA For Phase 3 Trials Of

Asimadoline 45

Sucampo Files 'Demand for Arbitration' Against Takeda 46

Abbott Takes Over Solvay Pharmaceuticals 46

SK Holdings Obtains IND Approval from FDA for YKP10811 47

MicroDose Takes Over Epix's Portfolio of Compounds 47

PPD Inks Agreement with Janssen Pharmaceutica 47

Warner Chilcott Takes Over P&G's Global Branded Prescription

Pharmaceutical Business 48

Abbott Acquires Solvay's Pharmaceutical Business 48

Tioga and Ono Ink Licensing Agreement for IBS Drug Development 48

Lexicon Reacquires Joint Venture Rights from Symphony 49

Ironwood Enters into Partnership with Almirall 49

Pawfect Foods Takes Over Synergy Pharmaceuticals 49

Tioga and US FDA Agree on SPA for Phase 3 Efficacy Protocols

of Asimadoline in IBS-D 50

Sucampo Obtains FDA Approval for AMITIZA for IBS-C in Adult Women 50

Apex and Dynogen Dissolve Merger Agreement 51

Rose Pharma and Eli Lily Ink Licensing Agreement Pertaining to

Compound for IBS Treatment 51

Napo and Trine Terminate License Agreement for Crofelemer 52

9. PRODUCT INRODUCTIONS/INNOVATIONS 53

Cedars-Sinai Medical Center Introduces Rifaximin for IBS Patients 53

Lesaffre Introduces Probiotic Yeast to Treat Intestinal

Discomfort 53

Lifeway Foods Launches BioKefir Range of Probiotic Drinks 53

Mayo Clinic Discovers Novel Genetic Variants in Serotonin Genes 54

Jarrow Formulas® to Introduce Ideal Bowel Support 299v® 54

Buscopan Launches Online Interactive Resource for IBS Patient 54

Chongqing Fortune Introduces Traditional Chinese Medicine 55

Alimentary Health to Introduce New Probiotic Treatment 55

Alimentary Health to Launch IBS Treatment 55

Astellas Pharma Introduces Irribow for Irritable Bowel Syndrome 55

10. FOCUS ON SELECT PLAYERS 56

Abbott Laboratories (US) 56

Alimentary Health Limited (Ireland) 56

Edusa Pharmaceuticals (US) 56

Ironwood Pharmaceuticals, Inc. (US) 57

Forest Laboratories, Inc. (US) 57

Lexicon Pharmaceuticals (US) 57

Pharmos Corporation (US) 58

Salix Pharmaceuticals, Inc. (US) 59

Sucampo Pharmaceuticals, Inc. (US) 59

Tioga Pharmaceuticals, Inc. (US) 59

11. GLOBAL MARKET PERSPECTIVE 61

Table 2: World Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome (IBS) by Geographic Region - US,

Japan, Europe, Rest of World Market Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2009

through 2017 (includes corresponding Graph/Chart) 61

Table 3: World Historic Review for Irritable Bowel Syndrome

(IBS) by Geographic Region - US, Japan, Europe, and Rest of

World Market Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 62

Table 4: World 15-Year Perspective for Irritable Bowel

Syndrome (IBS) by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Japan, Europe, and Rest of World for

Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 63

12. THE UNITED STATES 64

A.Market Analysis 64

An Overview 64

Prevalence of IBS-C in the US 64

US Leads the Global IBS Drug Development Scenario 64

High Unmet Needs Characterize the IBS Market 65

New Drugs Releases Likely to Drive Market Growth in the Near

Future 65

Irritable Bowel Syndrome: Key Facts 65

Drugs Approved for Use in IBS Treatment 66

Amitiza 66

Zelnorm 66

Lotronex 66

Strategic Corporate Developments 67

Focus on Select Major Players 76

Abbott Laboratories (US) 76

Edusa Pharmaceuticals (US) 76

Ironwood Pharmaceuticals, Inc. (US) 76

Forest Laboratories, Inc. (US) 77

Lexicon Pharmaceuticals (US) 77

Pharmos Corporation (US) 78

Salix Pharmaceuticals, Inc. (US) 78

Sucampo Pharmaceuticals, Inc. (US) 79

Tioga Pharmaceuticals, Inc. (US) 79

B.Market Analytics 80

Table 5: The US Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 80

Table 6: The US Historic Review for Irritable Bowel Syndrome

Market Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 80

13. JAPAN 81

A.Market Analysis 81

Strategic Corporate Development 81

Product Introductions/Innovation 81

B.Market Analytics 82

Table 7: Japanese Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 82

Table 8: Japanese Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 82

14. EUROPE 83

Market Analysis 83

Table 9: European Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome (IBS) by Geographic Region -

France, Germany, Italy, UK, Spain, Russia, and Rest of

Europe Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 83

Table 10: European Historic Review for Irritable Bowel

Syndrome (IBS) by Geographic Region - France, Germany,

Italy, UK, Spain, Russia, and Rest of Europe Market

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 84

Table 11: European 15-Year Perspective for RNA Interference

Application by Geographic Region - Percentage Breakdown of

Dollar Sales for France, Germany, Italy, UK, Spain, Russia,

and Rest of Europe for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 85

14a. FRANCE 86

Market Analysis 86

Table 12: French Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 86

Table 13: French Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 86

14b. GERMANY 87

Market Analysis 87

Table 14: German Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 87

Table 15: German Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 87

14c. ITALY 88

Market Analysis 88

Table 16: Italian Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 88

Table 17: Italian Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 88

14d. THE UNITED KINGDOM 89

A.Market Analysis 89

Product Introductions/Innovation 89

B.Market Analytics 89

Table 18: The UK Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 89

Table 19: The UK Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 90

14e. SPAIN 91

A.Market Analysis 91

Strategic Corporate Development 91

B.Market Analytics 92

Table 20: Spanish Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 92

Table 21: Spanish Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 92

14f. RUSSIA 93

Market Analysis 93

Table 22: Russian Recent Past, Current & Future Analysis for

Irritable Bowel Syndrome Market Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 93

Table 23: Russian Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 93

14g. REST OF EUROPE 94

A.Market Analysis 94

Strategic Corporate Developments 94

Product Introductions/Innovations 95

Focus on Select Key Player 96

Alimentary Health Limited (Ireland) 96

B.Market Analytics 97

Table 24: Rest of European Recent Past, Current & Future

Analysis for Irritable Bowel Syndrome Market Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2009 through 2017 (includes corresponding Graph/Chart) 97

Table 25: Rest of European Historic Review for Irritable

Bowel Syndrome Market Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 97

15. REST OF WORLD 98

A.Market Analysis 98

Strategic Corporate Developments 98

Product Introductions/Innovation 99

B.Market Analytics 99

Table 26: Rest of World Recent Past, Current & Future

Analysis for Irritable Bowel Syndrome Market Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2009 through 2017 (includes corresponding Graph/Chart) 99

Table 27: Rest of World Historic Review for Irritable Bowel

Syndrome Market Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) 100

COMPETITIVE LANDSCAPE

Total Companies Profiled: 50 (including Divisions/Subsidiaries - 51)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 27

Canada 1

Japan 5

Europe 16

France 2

Germany 1

The United Kingdom 3

Italy 2

Spain 1

Rest of Europe 7

Asia-Pacific (Excluding Japan) 2

------------------------------------------

To order this report:

Drug and Medication Industry: Global Irritable Bowel Syndrome (IBS) Therapeutics Industry

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com